Astrana Health, Inc. (NASDAQ:ASTH) Receives $63.67 Consensus Price Target from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $63.67.

A number of equities analysts have recently commented on the stock. TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They set a "buy" rating and a $66.00 price target on the stock. Robert W. Baird increased their price target on Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Truist Financial reduced their target price on Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, January 13th. Macquarie upgraded shares of Astrana Health to a "hold" rating in a research report on Monday, December 16th. Finally, KeyCorp began coverage on shares of Astrana Health in a research note on Friday, October 11th. They set a "sector weight" rating for the company.

Institutional Investors Weigh In On Astrana Health

Several hedge funds and other institutional investors have recently made changes to their positions in ASTH. SG Americas Securities LLC acquired a new position in Astrana Health during the 3rd quarter valued at about $680,000. Handelsbanken Fonder AB purchased a new stake in Astrana Health in the 3rd quarter valued at $492,000. GAMMA Investing LLC bought a new position in Astrana Health during the 3rd quarter valued at $34,000. Everence Capital Management Inc. purchased a new position in Astrana Health during the 3rd quarter worth $272,000. Finally, Guidance Capital Inc. bought a new stake in shares of Astrana Health in the 3rd quarter worth $724,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Price Performance

Shares of ASTH stock traded up $0.20 on Wednesday, reaching $35.78. The company had a trading volume of 211,638 shares, compared to its average volume of 347,777. The business's 50-day moving average is $35.61 and its 200 day moving average is $45.89. The stock has a market capitalization of $2.01 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20. Astrana Health has a one year low of $29.08 and a one year high of $63.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. During the same period last year, the company earned $0.47 earnings per share. Equities research analysts forecast that Astrana Health will post 1.15 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.